Clinical trial
A Study to Test the Safety/ Efficacy of Brivaracetam (BRV) Used as Adjunctive…
NCT03250377 · UCB Biopharma SRL, Industry · Completed
Key facts
| NCT number | NCT03250377 |
|---|---|
| Title | A Study to Test the Safety/ Efficacy of Brivaracetam (BRV) Used as Adjunctive Treatment in Subjects >=16 Years of Age With Partial Seizures With or Without Secondary Generalization |
| Official title | An Open-Label, Multicenter, Follow-up Study to Evaluate the Long-Term Safety and Efficacy of Brivaracetam Used as Adjunctive Treatment in Subjects >=16 Years of Age With Partial Seizures With or Without Secondary Generalization |
| Lead sponsor | UCB Biopharma SRL, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Partial Seizures With or Without Secondary Generalization, Epilepsy |
| Intervention type | Drug |
| Interventions | Brivaracetam |
| Enrollment | 207 |
| Start date | Aug 5, 2017 |
| Primary completion | Dec 24, 2024 |
| Completion | Dec 24, 2024 |
| First posted | Aug 15, 2017 |
| Last update posted | Jul 29, 2025 |
| Countries | China, Japan |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: